Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action Against Abeona Therapeutics Inc. (ABEO), AZZ, Inc. (AZZ) & Bloom Energy Corporation (BE)

ABEO, BE

NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. 

Abeona Therapeutics Inc. (NASDAQ: ABEO)
Class Period: May 31, 2018 - September 23, 2019
Deadline: January 2, 2020
For more info: www.bgandg.com/abeo
The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Abeona’s Chemical, Manufacturing and Controls (“CMC”) and internal controls and procedures and/or compliance policies were inadequate; (2) as a result, the Company failed to provide sufficient data points on the transport stability of EB-101 to clinical sites, or else such transport stability was insufficient; (3) consequently, it was foreseeable that the U.S. Food and Drug Administration (“FDA”) would reject approval for the start of the VITAL Study until such issues were addressed; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.

AZZ, Inc. (NYSE: AZZ)
Class Period: July 3, 2018 - October 8, 2019
Deadline: January 3, 2020
For more info: www.bgandg.com/azz  
The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) AZZ’s internal controls over financial reporting were not effective; (2) AZZ improperly implemented ASC 606 which resulted in improper revenue reconciliations; and (3) as a result of the foregoing, defendants’ positive statements about AZZ’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Bloom Energy Corporation (NYSE: BE)
Class Period: (1) purchased or otherwise acquired Bloom securities pursuant and/or traceable to Bloom’s Registration Statement issued in connection with Bloom’s July 2018 initial public stock offering (the “IPO” or “Offering”); or (2) purchased the publicly traded securities of Bloom between July 26, 2018 and September 16, 2019 (the “Class Period”)
Deadline: January 3, 2020
For more info: www.bgandg.com/be
The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Bloom’s technology produced emissions comparable to that a modern natural gas plant; (2) Bloom’s estimates of useful life for its energy servers and fuel cells were inaccurate; (3) Bloom used misleading accounting to mask the effect of future servicing expenses; (4) consequently, Bloom will potentially be liable for up to $2.2 billion in undisclosed servicing liabilities; and (5) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. 

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

Primary Logo



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today